Minimally invasive therapies have gained traction in the management of structural heart disease, and the field continues to evolve.
The most established transcatheter heart valve procedure — transcatheter aortic valve replacement (TAVR) — has become the standard of care for severe aortic stenosis across a wide range of surgical risk. Transcatheter mitral valve replacement (TMVR) and transcatheter mitral valve repair (TMVr) devices continue to advance, too.
Purchase and download our new Medtech Market Special Report to receive a detailed market forecast, including sales growth forecasts for the individual companies in the space, including Edwards Lifesciences, Medtronic, Abbott and others.
This extensive, roughly 80-page report, authored by veteran industry analyst Carrie Neptune, includes an overview of transcatheter heart valve procedures, technologies and innovations, historical sales and forecast markets, growth rates by region (U.S. and international), competitive analysis/market share, leading competitors and emerging startups, corporate strategies, market drivers and limiters, and trends/opportunities.
Here’s a brief overview from our table of contents:
- Heart valve disease overview
- Transcatheter aortic valve replacement (TAVR) devices
- TAVR’s expansion to low-risk patients
- Transcatheter mitral valve replacement (TMVR) devices
- Transcatheter mitral valve repair (TMVr) devices
- Emerging technology
- Global market forecasts of TAVR, TMVR and TMVr
Produced by veteran industry analysts, our Medtech Market Intelligence Reports presently examine markets including continuous glucose monitors (CGMs), surgical robotics and transcatheter heart valves. Go here for a complete list of available reports.
